OTC Markets OTCQB - Delayed Quote USD

Harvard Apparatus Regenerative Technology Inc. (HRGN)

1.8580

0.0000

(0.00%)

At close: April 10 at 4:00:00 PM EDT

Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children’s Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia

Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, is proud to announce a new partnership with the renowned Capital Institute of Pediatrics in China to develop innovative treatments for Esophageal Atresia (EA) using our flagship Cellspan Esophageal

GlobeNewswire 5 months ago

HRGN
0.00%
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors

Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced the appointment of Mao Zhang as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance. Mr. Mao Zhang is the Fo

GlobeNewswire 7 months ago

HRGN
0.00%
Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial

Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced that it has raised approximately $5 million from a new investor in a private placement of its shares. Additional details are provided below. The funds will be used to accelerate the

GlobeNewswire 7 months ago

HRGN
0.00%
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights

Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024.Received $0.5 million in convertible debt from Company’s CEO in February 2024. Holliston, MA, May 13, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technolog

GlobeNewswire 10 months ago

HRGN
0.00%

Performance Overview

Return	HRGN	S&P 500 (^GSPC)
YTD	-37.65%	-10.43%
1-Year	-37.86%	+2.08%
3-Year	-67.97%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Harvard Apparatus Regenerative Technology Inc. (HRGN)

Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children’s Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia

Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors

Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial

Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights

Performance Overview